TNF and neoplasm: CRS is a well-recognized adverse effect of CAR-T therapy due to the expansion of CAR T cells and tumor cell apoptosis followed by an inflammatory response consisting of supraphysiological levels of interluekin-6, tumor necrosis factor (TNF), and activated T cells.